

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

**Date: 25<sup>th</sup> May, 2018**

To,  
**Bombay Stock Exchange Ltd.**  
**Department of Corporate Services**  
**25<sup>th</sup> Floor, P. J. Towers, Dalal Street,**  
**Mumbai-400 001**

**Script ID: 506365**

**SUBJECT: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31/03/2018, DECLARATION, FORM 'A' AND AUDITORS REPORT IN BOARD MEETING HELD ON 25<sup>TH</sup> MAY, 2018**

Dear Sirs,


Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on Friday, 25<sup>th</sup> May, 2018 at 04:00 P.M. at Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai – 400 001 approved the following:

1. Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018
2. Form 'A' for the year ended 31<sup>st</sup> March, 2018
3. Auditors Report on Standalone Financial Results for the year ended 31<sup>st</sup> March, 2018
4. Declaration regarding Audit Report with unmodified opinion

Thanking You.

Yours Faithfully,

**FOR CHEMO PHARMA LABORATORIES LIMITED**

  
**ASHOK SOMANI**  
**DIRECTOR**  
**(DIN NO. - 03063364)**



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2017-2018 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2017-2018, along with the Financial Results on 25<sup>th</sup> May, 2018. We hereby confirm that auditors have expressed an Un-modified Opinion in their Audit Reports on Standalone Financial Statements

1.	Name of the Company:	<b>CHEMO PHARMA LABORATORIES LIMITED</b>
2.	Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2018
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	
	• Audit Committee Chairman–Balkishan Lohia	

# CHEMO PHARMA LABORATORIES LIMITED





Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	<b>CHEMO PHARMA LABORATORIES LIMITED</b>
2.	Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2018
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	
	• Audit Committee Chairman–Balkishan Lohia	



**Auditor's Report on Standalone Financial Results of the Chemo Pharma Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To Board of Directors of **Chemo Pharma Laboratories Limited**

We have audited the quarterly Financial Results of Chemo Pharma Laboratories Limited ('the Company') for the quarter and year ended 31<sup>st</sup> March, 2018 attached herewith, being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirements) Regulations 2015, as modified. Attention is drawn to the fact that the figures for the quarter ended 31<sup>st</sup> March 2018 and the corresponding quarter ended in the previous year as reported in these Standalone Financial Results are the balancing figures between audited figures in respect of full Financial Year and the audited year to date figures up to the end of the third quarter of the relevant financial year.

These Financial Results have been prepared on the basis of the annual Ind AS financial statements and audited quarterly Financial Results up to the end of the third quarter, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these Financial Results based on our audit of such Annual Ind AS Financial Statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ('Ind AS'), prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued there-under, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Financial Results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

## Opinion

In our opinion and to the best of our information and according to the explanations given to us these Financial Results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 in this regard; and
- (ii) gives a true and fair view of the net profit and other financial information for the year ended 31<sup>st</sup> March 2018.

For VMD & Co.  
Chartered Accountants  
FRN: 125002W

  
CA Amit Ganpule  
Partner

MRN: 114222  
Place : Mumbai  
Date: May 25, 2018  
No. : C/04/0518



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2018


Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended		Year Ended	
		31st March 2018	31st March 2017	31st March 2018	31st March 2017
		Unaudited	Unaudited	Audited	Audited
I	Revenue from Operations				-
II	Other Income	4,112	53,114	11,055	56,080
III	<b>Total Revenue (I + II)</b>	<b>4,112</b>	<b>53,114</b>	<b>11,055</b>	<b>56,080</b>
IV	<b>Expenses</b>				
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	397	234	1,564	805
	(5) Depreciation and Amortisation Expenses	35	-	35	-
	(6) Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown separately)	66	471	417	872
	i) Professional Charges	256	409	991	699
	ii) Share Registry Expenses	23	26	100	92
	iii) Annual Listing Fees	-	-	315	256
	(7) Finance Costs	-	-	-	-
	<b>Total Expenses</b>	<b>777</b>	<b>1,140</b>	<b>3,422</b>	<b>2,724</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>3,335</b>	<b>51,975</b>	<b>7,633</b>	<b>53,356</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>3,335</b>	<b>51,975</b>	<b>7,633</b>	<b>53,356</b>
VIII	Extra Ordinary Items	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>3,335</b>	<b>51,975</b>	<b>7,633</b>	<b>53,356</b>
X	Tax Expenses				
	(1) Current Tax	1,450	6,515	1,450	6,515
	(2) Tax Adjustment Previous Year	-	-	5,177	-
	(3) Deferred Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	<b>1,885</b>	<b>45,460</b>	<b>1,006</b>	<b>46,841</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>1,885</b>	<b>45,460</b>	<b>1,006</b>	<b>46,841</b>
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	<b>1,885</b>	<b>45,460</b>	<b>1,006</b>	<b>46,841</b>
XVIII	<b>Earnings per Share :</b>				
	(1) Basic	<b>1.26</b>	<b>30.31</b>	<b>0.67</b>	<b>31.23</b>
	(2) Diluted				

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.

- 2 The above Audited Financial Results for the Quarter and Year Ended 31.03.2018 have been reviewed by the Audit Committee in their Meeting held on 25.05.2018 and approved by the Board of Directors of its Meeting held on 25.05.2018. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

By Order of the Board  
For Chemo - Pharma Laboratories Limited



**ASHOK SOMANI**  
**DIRECTOR**

**Place : Mumbai**  
**Date : 25th May, 2018**




# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301  
 • Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001  
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2018 (Rupees in Thousands)

Sr. No.	PARTICULARS	As at 31.03.2018 Audited	As at 31.03.2017 Audited
1	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	<b>(A) Fixed Assets</b>		
	Tangible Assets	21	94
	<b>(B) Financial Assets</b>		
	(i) Investment	187	187
	(ii) Long Term Loans	16,884	15,670
2	<b>Current Assets</b>		
	(i) Cash & Cash Equivalents	76,637	68,734
	(ii) Short Term Loans	8,835	22,505
	<i>Sub Total</i>	<b>85,472</b>	<b>91,239</b>
	<b>GRAND TOTAL</b>	<b>102,564</b>	<b>107,190</b>
2	<b>EQUITY AND LIABILITIES</b>		
	<b>EQUITY</b>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	86,232	85,226
	<i>Sub Total</i>	<b>101,232</b>	<b>100,226</b>
1	<b>Non-Current Liabilities</b>		
	<b>(A) Financial Liabilities</b>		
	(i) Long Term Borrowings	1,197	1,197
2	<b>Current Liabilities</b>		
	(i) Short-Term Borrowings	-	-
	(ii) Other Current Liabilities	69	276
	(iii) Short-Term Provisions	66	5,491
	<i>Sub Total</i>	<b>135</b>	<b>5,767</b>
	<b>GRAND TOTAL</b>	<b>102,564</b>	<b>107,190</b>

By Order of the Board  
 For Chemo - Pharma Laboratories Limited



**ASHOK SOMANI**  
 DIRECTOR

Place : Mumbai  
 Date : 25th May, 2018





# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2018


(Rs. in Thousand)

PARTICULARS	STANDLONE	
	AUDITED QUARTER ENDED 31.03.2018	AUDITED YEAR ENDED 31.03.2018
<b>Reconciliation of Profit After Tax as reported earlier:</b>		
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>4,112.00</b>	<b>11,055.00</b>
<b>Benefit / (Charge):</b>	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>4,112.00</b>	<b>11,055.00</b>

By Order of the Board  
For Chemo - Pharma Laboratories Limited

Place : Mumbai  
Date : 25th May, 2018



  
ASHOK SOMANI  
DIRECTOR